GlaxoSmithKline(GSK) has announced that the Medicines Control Council (MCC) has granted registration for its cervical cancer vaccine. The registration allows for the use of the vaccine in South Africa.
GSK's cervical cancer vaccine is a human papillomavirus (HPV) vaccine indicated for the prevention of the precancerous cervical lesions associated with the most common cervical cancer-causing HPV types 16 and 18. GSK's cervical cancer vaccine is formulated with a novel proprietary adjuvant system called AS04, which is designed to enhance the immune response and increase the duration of protection against cancer-causing virus types.
A great step forward
"The decision to approve GSK's cervical cancer vaccine represents a great step forward for all South African women. It is a little-known yet disquieting fact that more women develop and die of cervical cancer than any other type of cancer in South Africa.
Physicians will now have access to this important vaccine to help protect women against this disease," said Dr Navin Singh, Medical Director of GSK.
Worldwide a woman dies of cervical cancer every two minutes. In South Africa these statistics are still worse. Here, each year approximately 6700 women will develop cervical cancer while an estimated 3700 will die from it. In South Africa a woman's risk of developing cervical cancer in her lifetime is one in 26.
According to Dr Singh, protection strategies against cervical cancer should include routine screening together with a vaccine designed to provide targeted, durable protection against the most common cancer-causing types. - (Health24)